PET/CT helps predict survival of patients with prostate cancer

06/26/2013 | MolecularImaging.net

Metabolic imaging using 18F-FDG-PET/CT helps predict the overall survival of patients with castrate-resistant metastatic prostate cancer, according to a study published in The Journal of Nuclear Medicine. Data provided by the imaging method "may be useful in assessing the comparative effectiveness of various conventional and emerging treatment strategies," researchers said.

View Full Article in:

MolecularImaging.net

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Paralegal
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC